Inhibrx Biosciences is a clinical-stage biotech developing engineered biologic cancer therapies based on a proprietary single-domain antibody platform. Lead candidates include ozekibart (INBRX-109), a multivalent DR5 agonist studied in sarcomas and other solid tumors, and INBRX-106, a hexavalent OX40 agonist in immuno-oncology. The company focuses on multivalent protein designs intended to balance potent tumor targeting with manageable safety.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -43.3 | — |
| Q2 2025 | 1.3 | — | -28.6 | — |
| Q3 2025 | 0 | — | -35.3 | — |
| Q4 2025 | 0 | — | -32.8 | — |
| Q1 2026 | 0 | — | -33.4 | — |
| Q2 2026 | 0 | -100% | -36.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Peoples Bancorp Inc. (PEBO), HBT Financial, Inc. (HBT), Perella Weinberg Partners (PWP), Afya Limited (AFYA), Elemental Royalty Corporation (ELE), ORIC Pharmaceuticals, Inc. (ORIC)